| Notice |
|---|
-
TECHNOLOGYCeliVax, Original Technology for Anti-Cancer Immunotherapeutic Vaccine
CeliVax uses B cells, NK cells and monocytes of patients
CeliVax is an original technology applicable on all cancers with verified antigen.
CeliVax is composed of 3 main parts, antigen-presenting cell, antigen gene, and adjuvant more -
A COVID-19 preventive vaccine developed using adenovirus vector-based technology.
It utilizes a safe, non-replicating recombinant adenovirus, established through years of research.
The vaccine employs a structurally stable and highly expressed COVID-19 spike protein, designed for optimal performance.
Optimized for rapid adenovirus vaccine production, it enables a swift response to COVID-19 variants. more
PIPELINE
We are currently developing various types of pipelines that introduce diverse cancer antigen genes based on the original CeliVax technology. Additionally, we are developing a COVID-19 preventive vaccine based on Cellid’s proprietary adenovirus vector platform technology. Meet Cellid’s pipelines that aim to address various unmet medical needs.
more
IR
Based on Cellid's core competence, we promise to seek the driving force for future growth through continuous growth.
Promotion Center
Cellid suggests independent and new paradigm of anti-cancer immunotherapy to pursue health and happy life of all people.
Recruitment Information
Cellid is waiting for talents to grow up with. Apply for Cellid now.
Copyright © CELLID. 2020 All Rights Reserved.
